

Press release

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA

- **Patents covering the use of its drug candidate IFB-088 to treat Charcot-Marie-Tooth (CMT) disease granted in the EU and the USA**
- **IP Protection of IFB-088 for CMT until at least 2034**
- **Composition of matter claims protecting IFB-088 back-up compounds**

Nantes, France – June 27th, 2017. InFlectis BioScience SAS, a biopharmaceutical company specializing in the discovery and development of drugs to treat orphan and non-orphan protein conformational disorders, today announced the strengthening of its intellectual property portfolio in Europe and in the USA with the issuance of two patents entitled *“Benzylidene guanidine derivatives and therapeutic use for the treatment of protein misfolding diseases”*.

In Europe, the patent EP2943467 protects new chemical compounds, as well as the use of benzylidene guanidine derivatives, including drug candidate IFB-088, in treating the hereditary peripheral neuropathy Charcot-Marie-Tooth disease, Amyotrophic Lateral Sclerosis, and retinal diseases, among others. This European patent is enforced in approximately 30 European countries, including France, Germany, UK, Italy, Spain, and the Netherlands, and is currently scheduled to remain in force until January 10th, 2034. The corresponding US patent N°9,682,943 protects the use of benzylidene guanidine derivatives, including drug candidate IFB-088, in treating Charcot-Marie-Tooth disease. In both cases, the patent term could further be extended with a maximum of five years based on future marketing authorizations.

Prosecution of the corresponding patent applications in other territories including Canada, Japan and China is ongoing.

InFlectis BioScience and the UK’s Medical Research Council (MRC) are the co-owners of this patent family, for which InFlectis BioScience has executed in 2014 an exclusive worldwide license agreement with the MRC to exploit the MRC’s co-ownership rights. According to the license agreement provision, InFlectis BioScience leads on the prosecution and the maintenance of this patent family.

Intellectual Property constitutes a key asset of InFlectis BioScience and is at the heart of its R&D projects. The company’s patent portfolio now comprises 7 families of published patents including 89 patents applications and patents related mainly to second generation of Benzylidene guanidine derivatives or new therapeutic compositions for the treatment of protein conformational disorders. Granted patents account for more than 50% of this portfolio and provide InFlectis BioScience’s drug candidates with long term protection.

Pierre Miniou, CBO of InFlectis BioScience SAS said: *“We remain focused on developing our therapeutic assets, specially our drug candidate IFB-088 for the treatment of CMT. The patent protection of the therapeutic use*

of IFB-088 in CMT, obtained in Europe and in the USA, will nicely complement the ten and seven-year period of marketing exclusivity associated with the orphan drug designation we obtained from the EMA and FDA. In parallel, the potential of our PPP1R15A inhibitors family provides significant opportunity in a variety of orphan and non-orphan protein misfolding diseases. We will continue to build up our IP portfolio along with the development of our pipeline programs”.

Notes for editors:

ABOUT IFB-088 (also known as Sephin1)

IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a promising pharmacokinetic profile for targeting the central and peripheral nervous system. IFB-088 is a selective inhibitor of PPP1R15A (GADD34), a stress-induced PP1 phosphatase regulatory subunit involved in the unfolded protein response. PPP1R15A inhibition by IFB-088 regulates the protein translation rate in stressed cells to a level manageable by the available cellular proteins that assist in protein folding (so-called “chaperones”), thereby restoring proteostasis. IFB-088 is strikingly specific for stressed cells, avoiding persistent inhibition of protein synthesis in normal, non-stressed cells.

ABOUT INFLECTIS BIOSCIENCE (www.inflectisbioscience.com)

InFlectis BioScience aims to discover and develop new molecules for the treatment of protein misfolding diseases. The company plans to demonstrate the clinical effectiveness of its drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth diseases type 1A (CMT-1A), then partner with a pharmaceutical company for its subsequent development and commercialization. The company is also developing IFB-088 for the treatment of rare eye diseases. Meanwhile, InFlectis BioScience develops new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of proteins in the endoplasmic reticulum. Based in Nantes in Western France, InFlectis BioScience is supported by Atlanpole (www.atlanpole.com), the science park of the economic area of Nantes Atlantique.

ABOUT THE MEDICAL RESEARCH COUNCIL (www.mrc.ac.uk)

The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms.

INFLECTIS BIOSCIENCE SAS

Philippe Guedat

President and CEO

philippeguedat@inflectisbioscience.com

Pierre Miniou

Chief Business Officer

pierreminiou@inflectisbioscience.com